Dillon & Associates’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-2,078
| Closed | -$218K | – | 77 |
|
|
2025
Q4 | $218K | Buy |
+2,078
| New | +$195K | 0.03% | 75 |
|
|
2025
Q2 | – | Sell |
-2,753
| Closed | -$248K | – | 78 |
|
|
2025
Q1 | $248K | Sell |
2,753
-287
| -9% | -$26.8K | 0.04% | 74 |
|
|
2024
Q4 | $301K | Sell |
3,040
-481
| -14% | -$49.6K | 0.04% | 73 |
|
|
2024
Q3 | $401K | Buy |
3,521
+70
| +2% | +$8.32K | 0.06% | 65 |
|
|
2024
Q2 | $428K | Buy |
3,451
+75
| +2% | +$9.66K | 0.06% | 65 |
|
|
2024
Q1 | $446K | Sell |
3,376
-75
| -2% | -$9.24K | 0.07% | 65 |
|
|
2023
Q4 | $376K | Sell |
3,451
-145
| -4% | -$15.1K | 0.07% | 64 |
|
|
2023
Q3 | $370K | Buy |
3,596
+73
| +2% | +$7.87K | 0.07% | 63 |
|
|
2023
Q2 | $405K | Hold |
3,523
| – | – | 0.07% | 64 |
|
|
2023
Q1 | $373K | Buy |
3,523
+110
| +3% | +$11.9K | 0.07% | 67 |
|
|
2022
Q4 | $379K | Sell |
3,413
-5
| -0.1% | -$511 | 0.08% | 62 |
|
|
2022
Q3 | $294K | Hold |
3,418
| – | – | 0.07% | 62 |
|
|
2022
Q2 | $311K | Sell |
3,418
-275
| -7% | -$24.4K | 0.07% | 60 |
|
|
2022
Q1 | $303K | Sell |
3,693
-1,483
| -29% | -$117K | 0.06% | 61 |
|
|
2021
Q4 | $399K | Sell |
5,176
-1,895
| -27% | -$151K | 0.07% | 58 |
|
|
2021
Q3 | $530K | Sell |
7,071
-4,792
| -40% | -$364K | 0.1% | 55 |
|
|
2021
Q2 | $925K | Sell |
11,863
-2,262
| -16% | -$168K | 0.18% | 48 |
|
|
2021
Q1 | $1.04M | Sell |
14,125
-288
| -2% | -$21.2K | 0.22% | 47 |
|
|
2020
Q4 | $1.13M | Buy |
14,413
+1,471
| +11% | +$113K | 0.24% | 46 |
|
|
2020
Q3 | $1.02M | Buy |
12,942
+633
| +5% | +$49.6K | 0.25% | 47 |
|
|
2020
Q2 | $904K | Buy |
12,309
+2,060
| +20% | +$155K | 0.24% | 46 |
|
|
2020
Q1 | $753K | Buy |
10,249
+1,671
| +19% | +$131K | 0.25% | 45 |
|
|
2019
Q4 | $745K | Buy |
8,578
+5,298
| +162% | +$435K | 0.21% | 47 |
|
|
2019
Q3 | $263K | Hold |
3,280
| – | – | 0.08% | 60 |
|
|
2019
Q2 | $263K | Hold |
3,280
| – | – | 0.08% | 61 |
|
|
2019
Q1 | $260K | Hold |
3,280
| – | – | 0.08% | 60 |
|
|
2018
Q4 | $238K | Hold |
3,280
| – | – | 0.09% | 60 |
|
|
2018
Q3 | $222K | Buy |
+3,280
| New | +$209K | 0.07% | 68 |
|
|
2017
Q4 | – | Sell |
-3,280
| Closed | -$200K | – | 70 |
|
|
2017
Q3 | $200K | Hold |
3,280
| – | – | 0.08% | 69 |
|
|
2017
Q2 | $200K | Sell |
3,280
-90
| -3% | -$5.48K | 0.08% | 70 |
|
|
2017
Q1 | $206K | Buy |
+3,370
| New | +$204K | 0.09% | 71 |
|
Other funds holding MRK
VCM
VPM
Dillon & Associates's MRK Position: Q1 2026 in Review
Dillon & Associates sold out of Merck (MRK) in Q1 2026, closing a stake of 2,078 shares — an estimated $218K sold.
Dillon & Associates first reported a position in MRK in Q1 2017 and held it in 31 quarters. The position peaked at $1.13M in Q4 2020. 3,780 funds tracked by Wall St. Rank hold MRK as of Q1 2026.
- Dillon & Associates reported no remaining Merck position as of Q1 2026 after selling out during the quarter.
- Dillon & Associates sold 2,078 Merck shares in Q1 2026, an estimated $218K.
- Dillon & Associates first reported a position in Merck in Q1 2017 and held it in 31 quarters.
- Dillon & Associates's Merck position peaked at $1.13M in Q4 2020.
- 3,780 funds tracked by Wall St. Rank held Merck as of Q1 2026.
Based on Dillon & Associates's 13F filing for Q1 2026, filed 7 May 2026.